These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 19961955)

  • 1. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM; Cassier PA; de Bono J
    Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A; Massard C; Soria JC
    Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience.
    Morgenstern DA; Hargrave D; Marshall LV; Gatz SA; Barone G; Crowe T; Pritchard-Jones K; Zacharoulis S; Lancaster DL; Vaidya SJ; Chisholm JC; Pearson AD; Moreno L
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):218-23. PubMed ID: 24322496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifying phase I methodology to facilitate enrolment of molecularly selected patients.
    Hollebecque A; Postel-Vinay S; Verweij J; Demetri GD; Flaherty K; Bedard P; Soria JC
    Eur J Cancer; 2013 May; 49(7):1515-20. PubMed ID: 23333057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fit-for-purpose biomarker method validation in anticancer drug development.
    Cummings J; Ward TH; Dive C
    Drug Discov Today; 2010 Oct; 15(19-20):816-25. PubMed ID: 20708097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The quest for biomarkers in tuberculosis.
    Parida SK; Kaufmann SH
    Drug Discov Today; 2010 Feb; 15(3-4):148-57. PubMed ID: 19854295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualification of imaging biomarkers for oncology drug development.
    Waterton JC; Pylkkanen L
    Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I cancer trials methodology].
    Le Tourneau C; Faivre S; Raymond E; Diéras V
    Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody positron emission tomography imaging in anticancer drug development.
    Lamberts LE; Williams SP; Terwisscha van Scheltinga AG; Lub-de Hooge MN; Schröder CP; Gietema JA; Brouwers AH; de Vries EG
    J Clin Oncol; 2015 May; 33(13):1491-504. PubMed ID: 25779566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.